Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

I Puzanov; RK Amaravadi; GA McArthur; KT Flaherty; PB Chapman; JA Sosman; A Ribas; M Shackleton; P Hwu; B Chmielowski; KB Nolop; PS Lin; KB Kim

Journal article

Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

I Puzanov, RK Amaravadi, GA McArthur, KT Flaherty, PB Chapman, JA Sosman, A Ribas, M Shackleton, P Hwu, B Chmielowski, KB Nolop, PS Lin, KB Kim

European Journal of Cancer | ELSEVIER SCI LTD | Published : 2015

DOI: 10.1016/j.ejca.2015.04.010

Abstract

© 2015 Elsevier Ltd.Introduction: Vemurafenib induces tumour regression in most patients with BRAF V600E-mutant melanoma; eventually, most experience progressive disease (PD). Long-term follow-up of patients with BRAF V600E melanoma treated in the phase 1 vemurafenib trial is reported. Methods: Patients received vemurafenib 240-1120. mg (dose escalation cohort) or 960. mg (extension cohort) orally twice daily. Clinical response was evaluated every 8. weeks by Response Evaluation Criteria In Solid Tumors (RECIST). Patients with PD amenable to local therapy (surgery or radiotherapy) were allowed to continue vemurafenib after progression. Overall survival (OS) from time of treatment initiation ..

View full abstract